or
forgot password

Is VEGF a Useful Serum Biomarker for Patients Diagnosed With Meningioma or Glioma?


N/A
N/A
N/A
Not Enrolling
Both
Glioma, Meningioma

Thank you

Trial Information

Is VEGF a Useful Serum Biomarker for Patients Diagnosed With Meningioma or Glioma?


Inclusion Criteria:



- any patient presenting with glioma or meningioma

Exclusion Criteria:

- a different type of brain tumor

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

Determine if VEGF levels correlate with tumor progression or recurrence

Outcome Time Frame:

every one to three months

Safety Issue:

No

Principal Investigator

Richard A Rovin, MD, FACS

Investigator Role:

Principal Investigator

Investigator Affiliation:

Upper Michigan Brain Tumor Center

Authority:

United States: Institutional Review Board

Study ID:

MGH-VEGF-1

NCT ID:

NCT00985036

Start Date:

September 2009

Completion Date:

January 2012

Related Keywords:

  • Glioma
  • Meningioma
  • glioma
  • meningioma
  • VEGF
  • Glioma
  • Meningioma

Name

Location
Marquette General Hospital Marquette, Michigan  49855